SCHEMBL13128486

SCHEMBL13128486

O=C(N[C@@]1(C(=O)NCc2ccc(Nc3ccccc3C(F)(F)F)cc2)CCOC1)c1cc(O)[nH]n1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MT-CO2 P00403 1/20 0.34
CTDSP1 Q9GZU7 1/20 0.34
MYC P01106 1/20 0.34
MAX P61244 1/20 0.34
BDKRB1 P46663 1/20 0.34
HTT P42858 2/20 0.33
MAPK9 P45984 1/20 0.33
MAPK10 P53779 1/20 0.33
SCD O00767 6/20 0.33
NPC1 O15118 3/20 0.33
RAB9A P51151 3/20 0.33
MAPT P10636 3/20 0.33
KMT2A Q03164 2/20 0.33
NPSR1 Q6W5P4 2/20 0.33
TSHR P16473 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MEN1 O00255 1/20 0.33
XBP1 P17861 1/20 0.33
ALDH1A1 P00352 2/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13128465 0.89 PKM (0.37) MT-CO2CTDSP1MYCMAXHTT
SCHEMBL13128509 0.87 CTDSP1 (0.35) MT-CO2CTDSP1MYCMAXBDKRB1
SCHEMBL2808601 0.85 CTDSP1 (0.35) MT-CO2CTDSP1MYCMAXBDKRB1
SCHEMBL13128481 0.85 CTDSP1 (0.35) CTDSP1MYCMAXBDKRB1HTT
SCHEMBL2810328 0.84 BDKRB1 (0.37) MT-CO2CTDSP1MYCMAXBDKRB1
SCHEMBL2809658 0.83 CYP1A2 (0.39) BDKRB1NPC1RAB9AMAPTKMT2A
SCHEMBL13128480 0.83 CTDSP1 (0.35) CTDSP1MYCMAXBDKRB1HTT
SCHEMBL2809802 0.83 IDO1 (0.35) CTDSP1MYCMAXBDKRB1HTT
SCHEMBL2805620 0.83 HDAC1 (0.41) MT-CO2CTDSP1MYCMAXBDKRB1
SCHEMBL2804848 0.83 BDKRB1 (0.38) MT-CO2CTDSP1MYCMAXBDKRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130131075-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-23 US disclosed
US-20100240669-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed
US-20100240669-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed
WO-2010097372-A1 COMPOUNDS AS BRADYKININ B1 ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131075-A1 NEW COMPOUNDS ADORA1, H1-10, P2RY11 MT-CO2 1519/4885CTDSP1 4271/4885MYC 4605/4885
US-20100240669-A1 NEW COMPOUNDS ADORA1, H1-10, P2RY11 MT-CO2 1519/4885CTDSP1 4271/4885MYC 4605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.